TY - JOUR
T1 - Single-cell analysis implicates Th17 to Th2 cell plasticity in the pathogenesis of palmoplantar pustulosis
AU - APRICOT and PLUM study team
AU - McCluskey, Daniel
AU - Benzian-Olsson, Natashia
AU - Mahil, Satveer K.
AU - Hassi, Niina Karoliina
AU - Wohnhaas, Christian T.
AU - Burden, A. David
AU - Griffiths, Christopher E.M.
AU - Ingram, John R.
AU - Levell, Nick J.
AU - Parslew, Richard
AU - Pink, Andrew E.
AU - Reynolds, Nick J.
AU - Warren, Richard B.
AU - Visvanathan, Sudha
AU - Baum, Patrick
AU - Barker, Jonathan N.
AU - Smith, Catherine H.
AU - Capon, Francesca
N1 - Funding Information:
Support was received from the Department of Health via the NIHR BioResource Clinical Research Facility and comprehensive Biomedical Research Centre awards to Guy's and St Thomas’ NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust (guysbrc-2012-1). Support was also received from the Newcastle NIHR Biomedical Research Centre. The APRICOT trial was funded by the Efficacy and Mechanism Evaluation (EME) Programme, a UK Medical Research Council (M.R.C.) and NIHR partnership (grant EME 13/50/17 to C.H.S., F.C., J.N.B., A.D.B., R.B.W., N.J.R., and C.E.M.G.). This work was also supported by the European Academy of Dermatology and Venereology (grant PPRC-2018-25 to F.C. and J.N.B.) and the Psoriasis Association (grant BSTOP50/5 to C.H.S.). D.Mc. is supported by the Medical Research Council (MRC; grant MR/R015643/1) and King's College London as member of the MRC Doctoral Training Partnership in Biomedical Sciences. N.B.O. was funded by a NIHR predoctoral fellowship (grant NIHR300473). S.K.M. is funded by an MRC Clinical Academic Research Partnership award (MR/T02383X/1). C.E.M.G. is funded in part by the NIHR Manchester Biomedical Research Centre and is an NIHR emeritus senior investigator. N.J.R. is an NIHR senior investigator. He acknowledges support from the Newcastle MRC/EPSRC Molecular Pathology Node and the Newcastle NIHR Medtech and In Vitro Diagnostic Co-operative. R.B.W. is supported by the Manchester NIHR Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the MRC, NHS, NIHR, or the Department of Health. Disclosure of potential conflict of interest: F. Capon and J. N. Barker have received funding from Boehringer-Ingelheim. C. T. Wohnhaas, P. Baum and S. Visvanathan are Boehringer-Ingelheim employees. J. R. Ingram is editor in chief of the British Journal of Dermatology and receives an author honorarium from UpToDate. He is a consultant for UCB Pharma, Novartis, Boehringer Ingelheim, and ChemoCentryx and participated in advisory boards for Kymera Therapeutics and Viela Bio, all in the field of hidradenitis suppurativa. He is a co-copyright holder of the HiSQOL and Patient Global Assessment instruments for hidradenitis suppurativa. R. B. Warren has received research grant and/or consultancy fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, GSK, Janssen, Lilly, Leo, Medac, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and UNION. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
Support was received from the Department of Health via the NIHR BioResource Clinical Research Facility and comprehensive Biomedical Research Centre awards to Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust (guysbrc-2012-1). Support was also received from the Newcastle NIHR Biomedical Research Centre . The APRICOT trial was funded by the Efficacy and Mechanism Evaluation (EME) Programme, a UK Medical Research Council (M.R.C.) and NIHR partnership (grant EME 13/50/17 to C.H.S., F.C., J.N.B., A.D.B., R.B.W., N.J.R., and C.E.M.G.). This work was also supported by the European Academy of Dermatology and Venereology (grant PPRC-2018-25 to F.C. and J.N.B.) and the Psoriasis Association (grant BSTOP50/5 to C.H.S.). D.Mc. is supported by the Medical Research Council (MRC; grant MR/R015643/1) and King’s College London as member of the MRC Doctoral Training Partnership in Biomedical Sciences. N.B.O. was funded by a NIHR predoctoral fellowship (grant NIHR300473). S.K.M. is funded by an MRC Clinical Academic Research Partnership award (MR/T02383X/1). C.E.M.G. is funded in part by the NIHR Manchester Biomedical Research Centre and is an NIHR emeritus senior investigator. N.J.R. is an NIHR senior investigator. He acknowledges support from the Newcastle MRC/EPSRC Molecular Pathology Node and the Newcastle NIHR Medtech and In Vitro Diagnostic Co-operative. R.B.W. is supported by the Manchester NIHR Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the MRC, NHS, NIHR, or the Department of Health.
Publisher Copyright:
© 2022 The Authors
PY - 2022/10
Y1 - 2022/10
N2 - Background: Palmoplantar pustulosis (PPP) is a severe inflammatory skin disorder, characterised by eruptions of painful, neutrophil-filled pustules on the palms and soles. While PPP has a profound effect on quality of life, it remains poorly understood and notoriously difficult to treat. Objective: We sought to investigate the immune pathways that underlie the pathogenesis of PPP.Methods: We applied bulk- and single-cell RNA-sequencing methods to the analysis of skin biopsies and peripheral blood mononuclear cells. We validated our results by flow cytometry and immune fluorescence microscopyResults: Bulk RNA-sequencing of patient skin detected an unexpected signature of T-cell activation, with a significant overexpression of several Th2 genes typically upregulated in atopic dermatitis. To further explore these findings, we carried out single-cell RNA-sequencing in peripheral blood mononuclear cells of healthy and affected individuals. We found that the memory CD4+T-cells of PPP patients were skewed towards a Th17 phenotype, a phenomenon that was particularly significant among CLA+ skin-homing cells. We also identified a subset of memory CD4+ T-cells which expressed both Th17 (KLRB1/CD161) and Th2 (GATA3) markers, with pseudo-time analysis suggesting that the population was the result of Th17 to Th2 plasticity. Interestingly, the GATA3+/CD161+ cells were over-represented among the PBMCs of affected individuals, both in the scRNA-seq dataset and in independent flow-cytometry experiments. Dual positive cells were also detected in patient skin by means of immune fluorescence microscopy.Conclusions: These observations demonstrate that PPP is associated with complex T-cell activation patterns and may explain why biologics that target individual T-helper populations have shown limited therapeutic efficacy.
AB - Background: Palmoplantar pustulosis (PPP) is a severe inflammatory skin disorder, characterised by eruptions of painful, neutrophil-filled pustules on the palms and soles. While PPP has a profound effect on quality of life, it remains poorly understood and notoriously difficult to treat. Objective: We sought to investigate the immune pathways that underlie the pathogenesis of PPP.Methods: We applied bulk- and single-cell RNA-sequencing methods to the analysis of skin biopsies and peripheral blood mononuclear cells. We validated our results by flow cytometry and immune fluorescence microscopyResults: Bulk RNA-sequencing of patient skin detected an unexpected signature of T-cell activation, with a significant overexpression of several Th2 genes typically upregulated in atopic dermatitis. To further explore these findings, we carried out single-cell RNA-sequencing in peripheral blood mononuclear cells of healthy and affected individuals. We found that the memory CD4+T-cells of PPP patients were skewed towards a Th17 phenotype, a phenomenon that was particularly significant among CLA+ skin-homing cells. We also identified a subset of memory CD4+ T-cells which expressed both Th17 (KLRB1/CD161) and Th2 (GATA3) markers, with pseudo-time analysis suggesting that the population was the result of Th17 to Th2 plasticity. Interestingly, the GATA3+/CD161+ cells were over-represented among the PBMCs of affected individuals, both in the scRNA-seq dataset and in independent flow-cytometry experiments. Dual positive cells were also detected in patient skin by means of immune fluorescence microscopy.Conclusions: These observations demonstrate that PPP is associated with complex T-cell activation patterns and may explain why biologics that target individual T-helper populations have shown limited therapeutic efficacy.
KW - palmoplantar pustulosis
KW - PPP
KW - scRNA-Seq
KW - Single-cell RNA sequencing
KW - T-cell plasticity
UR - http://www.scopus.com/inward/record.url?scp=85131809077&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2022.04.027
DO - 10.1016/j.jaci.2022.04.027
M3 - Article
C2 - 35568077
AN - SCOPUS:85131809077
SN - 0091-6749
VL - 150
SP - 882
EP - 893
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 4
ER -